OM1, formerly Better Outcomes, is a health technology company focused on real-world outcomes for chronic conditions.

OM1 helps customers generate and use real-world evidence more rapidly and effectively to gain regulatory approval, understand the effectiveness, safety and value of treatments, and personalize care.

OM1 was founded in 2015 by Dr. Richard Gliklich. The company is headquartered in Boston, Massachusetts.

 

OM1 partners with providers, medical societies, payers, and manufacturers to harness real-world data for advancing medical research, evaluating health outcomes, obtaining regulatory approvals, and personalizing treatment in chronic disease areas.

 

OM1 leverages big data, standardized outcomes measurement, and artificial intelligence technology, to build the first intelligent data cloud for healthcare, enabling more precise information and better decision making for stakeholders across the healthcare ecosystem.

 

OM1's products include, in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), and state-of-the art AI solutions for measuring and predicting outcomes for patients and populations.

 

OM1 is backed by D1 Capital Partners, General Catalyst, Kaiser Permanente, Breyer Capital, Polaris Partners, Scale Venture Partners, and others. The company raised $85M in a new round on Jul 16, 2021. This brings OM1's total funding to $171M to date.

 

 

  • Year founded: 2015
  • Funding Info: $171M over 4 Rounds (Latest Funding Type: Series D)
  • Yearly Revenue: NA
  • Employee Size: 51-200
  • Business Valuation: NA
  • City/Town: Boston
  • State: Massachusetts
  • Country: United States
Related businesses